Assessing <scp>CYP</scp> 2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition

MLA

Jian Wang, et al. “Assessing CYP 2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition.” CPT: Pharmacometrics & Systems Pharmacology, vol. 8, Dec. 2018, pp. 158–66. EBSCOhost, https://doi.org/10.1002/psp4.12350.

APA

Jian Wang, Fang Wu, Lei Zhang, Peng Duan, Victor Crentsil, Jason N. Moore, Jeffrey W. Fisher, Gilbert J. Burckart, & Daniel Gonzalez. (2018). Assessing CYP 2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. CPT: Pharmacometrics & Systems Pharmacology, 8, 158–166. https://doi.org/10.1002/psp4.12350

Chicago

Jian Wang, Fang Wu, Lei Zhang, Peng Duan, Victor Crentsil, Jason N. Moore, Jeffrey W. Fisher, Gilbert J. Burckart, and Daniel Gonzalez. 2018. “Assessing CYP 2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition.” CPT: Pharmacometrics & Systems Pharmacology 8 (December): 158–66. doi:10.1002/psp4.12350.